← Leaderboards
Christoph Rader
Scripps Research Institute
$8,681,262
Attributed
$10,676,094
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2013–22$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,676,094 · 8
By mechanism
R01$8,058,316 · 4
U01$1,431,851 · 1
R21$897,626 · 2
R43$288,301 · 1
Top collaborators
- Ben Shen6 shared
- Natarajan Muthusamy2 shared
- Lori Hazlehurst1 shared
Most similar at Scripps Research Institute
Same institution · by research overlap
- Athina Markou$17,298,991
- Subhash C Sinha$3,568,854
- Robert L Sah$10,232,766
- Michael J Maccoss$32,266,775
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMonoclonal AntibodiesBaseMalignant NeoplasmsIn VitroValidationCancer TherapyEngineeringAntibodiesDesignSmall MoleculeCellsSpecificitySiteToxic EffectSelenocysteinePharmaceutical PreparationsT-LymphocyteTechnologySurface AntigensLysineNext GenerationDrug KineticsCytotoxicity
Grant awards (27)
T-cell engaging bispecific antibodies designed for proteolytic activation in the tumor microenvironment$211,895
R21 · FY2022 · CA · contact PI
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$575,010
R01 · FY2021 · CA · contact PI
Novel Enediyne-Based Antibody-Drug Conjugates for Cancers$535,980
R01 · FY2021 · CA
T-cell engaging bispecific antibodies designed for proteolytic activation in the tumor microenvironment$144,870
R21 · FY2021 · CA · contact PI
Novel Enediyne-Based Antibody-Drug Conjugates for Cancers$122,993
R01 · FY2021 · CA
T-cell engaging bispecific antibodies designed for proteolytic activation in the tumor microenvironment$114,593
R21 · FY2021 · CA · contact PI
Novel Enediyne-Based Antibody-Drug Conjugates for Cancers$658,973
R01 · FY2020 · CA
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$575,010
R01 · FY2020 · CA · contact PI
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$92,500
R01 · FY2020 · CA · contact PI
Novel Enediyne-Based Antibody-Drug Conjugates for Cancers$639,203
R01 · FY2019 · CA
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$557,760
R01 · FY2019 · CA · contact PI
Validation of Siglec-6 as a novel target for cancer immunotherapy$179,804
R21 · FY2019 · CA · contact PI
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$92,500
R01 · FY2019 · CA · contact PI
Novel Enediyne-Based Antibody-Drug Conjugates for Cancers$658,973
R01 · FY2018 · CA
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$575,010
R01 · FY2018 · CA · contact PI
Chemically Programmed Bispecific Antibodies for Cancer Therapy$398,400
R01 · FY2018 · CA · contact PI
Validation of Siglec-6 as a novel target for cancer immunotherapy$246,464
R21 · FY2018 · CA · contact PI
Novel Enediyne-Based Antibody-Drug Conjugates for Cancers$658,973
R01 · FY2017 · CA
Chemically Programmed Bispecific Antibodies for Cancer Therapy$398,400
R01 · FY2017 · CA · contact PI
Chemically Programmed Bispecific Antibodies for Cancer Therapy$398,400
R01 · FY2016 · CA · contact PI
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$487,154
U01 · FY2015 · CA · contact PI
Chemically Programmed Bispecific Antibodies for Cancer Therapy$398,400
R01 · FY2015 · CA · contact PI
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$465,155
U01 · FY2014 · CA · contact PI
Chemically Programmed Bispecific Antibodies for Cancer Therapy$392,175
R01 · FY2014 · CA · contact PI
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia$479,542
U01 · FY2013 · CA · contact PI
Increasing the efficacy of MTI-101 in MM using Ab conjugation strategies$288,301
R43 · FY2013 · CA
Gene transfer of antibodies targeting tumor angiogenesis$329,656
R01 · FY2002 · CA